Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) brutally perils physical and
mental health worldwide. Unavailability of effective anti-viral drug rendering global threat of …

The main protease (Mpro) of SARS-CoV-2 is a validated antiviral drug target. Several Mpro
inhibitors have been reported with potent enzymatic inhibition and cellular antiviral activity …

Highlights•The SARS-CoV-2 main protease is a prime drug target.•Coronavirus main
proteases share a structurally conserved substrate-binding region.•The structure and …

The emergence of severe acute respiratory syndrome (SARS-CoV-2) in 2019 marked the
third occurrence of a highly pathogenic coronavirus in the human population since 2003. As …

SARS-CoV-2 proteases Mpro and PLpro are promising targets for antiviral drug
development. In this study, we present an antiviral screening strategy involving a novel in …

SARS-CoV-2 is the causative agent of the COVID-19 pandemic. The approval of vaccines
and small-molecule antivirals is vital in combating the pandemic. The viral polymerase …

Effective, safe, and pharmacokinetically suitable drugs are urgently needed to curb the
ongoing COVID-19 pandemic. The main protease or 3C-like protease (Mpro or 3CLpro) of …

Highlights•The main protease, known as M pro, is encoded by the viral genome and is
essential for viral replication.•The effective target for drug development has been the M …

In this review, we collected 1765 severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) M-pro inhibitors from the bibliography and other sources, such as the COVID …

Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). The viral outbreak started in late 2019 and rapidly became a …